In an eight-week study of 15 patients, oral niacinamide added to standard phosphorus-lowering therapies resulted in a modest yet significant reduction in plasma phosphorus levels in patients on peritoneal dialysis, investigators reported in Peritoneal Dialysis International (2009;29:562-567).
Patients were randomized to receive niacinamide or placebo in addition to standard phosphate binders. Plasma phosphorus decreased by an average 0.7 mg/dL in the niacinamide group but increased by an average 0.4 mg/dL in the placebo arm.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.